BrainParrot

Work out a plan for capping prices of all drugs: SC to govt.

GS2Full notePublished: · Updated:

Source: The Hindu, 13 October 2026

Summary

  • The Centre told the Supreme Court it had decided to cap trade margins at 30% for non-scheduled cancer drugs. The cap covers both patented and non-patented medicines, as Solicitor-General Tushar Mehta told the Bench.
  • The Bench of Justices Vikram Nath and Sandeep Mehta called this commendable but inadequate. It asked why other essential medicines and medical devices were not also brought under the 16% retailer margin of the DPCO 2013.
  • The Bench gave the Centre until 27 October to work out the modalities for capping medicine prices, when the matter will be heard next.

UPSC relevance: GS2 — Health, Judiciary; GS3 — Economy: price regulation

Key facts for Prelims

  • DPCO 2013 is delegated legislation under the Essential Commodities Act, 1955 (Section 3). Para 7 allows a 16% margin to retailer when fixing ceiling prices of scheduled formulations and retail prices of new drugs.
  • MRP of scheduled formulations is ceiling price plus applicable local taxes.
  • Scheduled formulations are those in the First Schedule; non-scheduled drugs are outside it. The ceiling price is revised each 1 April on WPI.
  • NPPA was set up in 1997 under the Ministry of Chemicals and Fertilizers.
  • When DPCO 2013 came into force, 348 drugs covering about 652 formulations were brought under price control.
  • Related constitutional hooks: Article 21 and Article 47.

Data and details

  • Centre's decision: a 30% trade-margin cap for non-scheduled cancer drugs, covering patented and non-patented medicines.
  • Mark-ups between PTR and MRP reached up to 1,000% in some cases. The Bench called this "broad daylight dacoity".
  • The DPCO retailer margin is 16%. The Bench asked why other drugs and devices were excluded: "This is just the tip of the iceberg... What about other drugs".
  • An India-made cardiac stent costing about ₹5,000 was reportedly sold by hospitals for over ₹25,000. The Bench asked about the logic of allowing sale at "400 times the actual cost". The figures are as reported and not reconciled in the article.
  • The Bench noted that transport, raw material, R&D and ancillary costs are already included in the MRP.
  • Petitioners: advocate Kishan Chand Jain and paediatric surgeon Sanjay Kulshrestha, seeking stricter DPCO enforcement across the supply chain.
  • ASG Aishwarya Bhati cautioned against a uniform cap across all medicines. The Bench was not persuaded and said ensuring the availability of price-controlled medicines is the government's responsibility.
  • Deadline: 27 October for the Centre to work out the modalities.

Static–dynamic linkage

  • Medicines are treated as essential commodities. The Government regulates their price through delegated legislation, the Drugs (Prices Control) Order, so that essential and life-saving medicines stay affordable.
  • The constitutional backdrop is the right to life and health (Article 21) and the Directive Principle on improving public health (Article 47). The Supreme Court is using petitions on the enforcement of price control to push the executive towards wider regulation.
  • The debate is between a uniform price or margin cap, which the Additional Solicitor-General cautioned against, and a targeted, product-specific approach.

Syllabus mapping: GS3 – Economy: Government policies and interventions, pricing and regulation of essential goods; GS2 – Social Justice/Health: access to affordable healthcare; GS2 – Judiciary: judicial intervention in policy

Background primer

Drugs (Prices Control) Order, 2013 (DPCO 2013)

What it is:
DPCOs are issued under Section 3 of the Essential Commodities Act, 1955, to let the Government declare ceiling prices for essential and life-saving medicines.
Founded:
DPCO 2013 was issued by the Ministry of Chemicals and Fertilisers on 15 May 2013, based on the National Pharmaceutical Pricing Policy 2012, for medicines in the National List of Essential Medicines 2011. Earlier DPCOs (1970, 1979, 1987, 1995) were based on cost to manufacturers; the 2013 order moved to a market-based approach.
Mandate:
No one may sell a scheduled formulation above the price notified by the NPPA.
Why it matters:
Reasonable prices for essential medicines, with a margin built into the MRP.

National Pharmaceutical Pricing Authority (NPPA)

What it is:
An independent body of experts under the Ministry of Chemicals and Fertilizers.
Founded:
Established on 29 August 1997 through a Government of India Resolution, as an attached office of the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers).
Mandate:
Fixing and revising prices of pharmaceutical products, enforcing the DPCO, and monitoring prices of controlled and decontrolled drugs.
Why it matters:
Separating price-fixing expertise from routine ministerial administration.

Additional context

  • In February 2019 the NPPA invoked its extraordinary powers under Para 19 of DPCO 2013 to bring 42 non-scheduled anti-cancer drugs under price control through Trade Margin Rationalisation (TMR). Trade margin was capped at 30% of MRP, as a pilot or "proof of concept" for TMR.
  • Para 19 has also been used for other products. Coronary stents were put in Schedule-I of DPCO 2013 in December 2016, and their ceiling prices were notified on 13 February 2017. On 3 June 2021 the NPPA capped the trade margin on oxygen concentrators at 70% at the price-to-distributor level.
  • Press reports based on All India Radio (newsonair.gov.in) say the NPPA has since capped trade margins on 137 non-scheduled anti-cancer drugs at 30% of MRP under Para 19, building on the 2019 pilot. This is likely the measure the Centre described to the Court, but the article does not confirm the link.

Mains dimensions

  • Affordability and out-of-pocket expenditure: Mark-ups of up to 1,000% and device mark-ups defeat the aim of affordable healthcare. Patients bear the burden in the absence of strong insurance coverage.
  • Regulatory design: The case contrasts product-specific caps with a uniform cap, the Centre's caution against uniformity versus the Bench's insistence on a plan for all drugs. Trade margin rationalisation is a flexible tool because it works on distribution margins rather than manufacturer costs.
  • Medical devices and hospitals: The cardiac stent example shows pricing opacity at the hospital level, where MRP printed on the product does not protect patients.
  • Judicial role: The Court is pressing the executive for a policy-level plan, an example of judicial activism in socio-economic policy. This has to be balanced with separation of powers and economic expertise.
  • Industry concerns: The Additional Solicitor-General cautioned against a uniform cap across medicines. Industry is likely to argue R&D and supply costs, but the Bench replied that these are already included in MRP.
  • Way forward: A transparent, data-driven extension of trade-margin caps to essential medicines and devices, stronger NPPA enforcement and monitoring, and wider availability of generics.

Possible Mains question

**GS3/GS2, 15 marks:** "Excessive trade margins on essential medicines and medical devices undermine the right to health. Examine the adequacy of the existing price-control framework in India and discuss the role of the judiciary in pushing for regulatory reform."

Related topics

  • Essential Commodities Act, 1955; National List of Essential Medicines
  • NPPA and National Pharmaceutical Pricing Policy, 2012
  • Article 21 (right to health), Article 47; judicial activism and PIL
  • Jan Aushadhi / generic medicines; Ayushman Bharat and out-of-pocket expenditure

Topics: GS2Economy

How we write and check these notes →

All current affairs of 13 October 2026 → · UPSC Current Affairs